Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 10, 2016, Pages 1385-1397.e10

  Bonovas, Stefanos ^a   Fiorino, Gionata ^a   Allocca, Mariangela ^a   Lytras, Theodore ^b,c,d   Nikolopoulos, Georgios K ^d   Peyrin Biroulet, Laurent ^e   Danese, Silvio ^f  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d Hellenic Center for Disease Control and Prevention   (Greece)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f HUMANITAS UNIVERSITY   (Italy)

Author keywords

Anti TNF; Antibody; Cancer Risk Factor; Side Effect

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; NATALIZUMAB; PLACEBO; VEDOLIZUMAB; IMMUNOLOGIC FACTOR;

ARTICLE; CANCER RISK; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; EPSTEIN BARR VIRUS INFECTION; ESOPHAGUS CANDIDIASIS; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; INFECTION; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; JC VIRUS INFECTION; META ANALYSIS; NEOPLASM; NOCARDIOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS JIROVECII INFECTION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; THRUSH; TREATMENT OUTCOME; TUBERCULOSIS; ULCERATIVE COLITIS; ADVERSE EFFECTS; BIOLOGICAL THERAPY; COMPLICATION; GASTROINTESTINAL NEOPLASMS; INFLAMMATORY BOWEL DISEASES; NETWORK META-ANALYSIS; OPPORTUNISTIC INFECTIONS; PROCEDURES;

BIOLOGICAL THERAPY; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; NETWORK META-ANALYSIS; OPPORTUNISTIC INFECTIONS; PLACEBOS; TREATMENT OUTCOME;

EID: 84991037422     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.04.039     Document Type: Article

References (80)

1. 1 Danese, S., Vuitton, L., Peyrin-Biroulet, L., Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 12 (2015), 537–545.
2. 2 Danese, S., Fiorino, G., Peyrin-Biroulet, L., et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 160 (2014), 704–711.
3. 3 Hazlewood, G.S., Rezaie, A., Borman, M., et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology 148 (2015), 344–354.e5.
4. 4 Singh, S., Garg, S.K., Pardi, D.S., et al. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. Mayo Clin Proc 89 (2014), 1621–1635.
5. 5 Nyboe Andersen, N., Pasternak, B., Friis-Møller, N., et al. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ, 350, 2015, h2809.
6. 6 Deepak, P., Stobaugh, D.J., Ehrenpreis, E.D., Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointest Liver Dis 22 (2013), 269–276.
7. 7 Grijalva, C.G., Chen, L., Delzell, E., et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306 (2011), 2331–2339.
8. 8 Cipriani, A., Higgins, J.P., Geddes, J.R., et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159 (2013), 130–137.
9. 9 Mills, E.J., Thorlund, K., Ioannidis, J.P., Demystifying trial networks and network meta-analysis. BMJ, 346, 2013, f2914.
10. 10 Caldwell, D.M., Ades, A.E., Higgins, J.P., Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331 (2005), 897–900.
11. 11 Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies in inflammatory bowel disease and the risk of infections and malignancies: a systematic review and meta-analysis of harmful effects in randomized controlled trials. PROSPERO 2015:CRD42015027065. Available at: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015027065. Accessed June 30, 2016.
12. 12 Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration, 2011, version 5.0.1.
13. 13 Jansen, J.P., Fleurence, R., Devine, B., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices—part 1. Value Health 14 (2011), 417–428.
14. 14 Hoaglin, D.C., Hawkins, N., Jansen, J.P., et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14 (2011), 429–437.
15. 15 Hutton, B., Salanti, G., Caldwell, D.M., et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162 (2015), 777–784.
16. 16 Higgins, J.P., Altman, D.G., Gøtzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
17. 17 Bonovas, S., Lytras, T., Nikolopoulos, G., On the criteria used for assessing the risk of bias in randomized trials included in systematic reviews and meta-analyses addressing adverse effects. Eur J Epidemiol 30 (2015), 249–250.
18. 18 Sweeting, M.J., Sutton, A.J., Lambert, P.C., What to add to nothing? use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23 (2004), 1351–1375.
19. 19 Mantel, N., Haenszel, W., Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959), 719–748.
20. 20 DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
21. 21 Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994), 1088–1101.
22. 22 Egger, M., Davey Smith, G., Schneider, M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
23. 23 Cochran, W., The combination of estimates from different experiments. Biometrics 810 (1954), 101–129.
24. 24 Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
25. 25 Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
26. 26 Bucher, H.C., Guyatt, G.H., Griffith, L.E., et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50 (1997), 683–691.
27. 27 Heneghan, C., Badenoch, D., Evidence-based medicine toolkit. 2006, BMJ Books, Blackwell Publishing, Oxford, UK.
28. 28 R Development Core Team. R: a language and environment for statistical computing. 2014, R Foundation for Statistical Computing, Vienna, Austria.
29. 29 Schwarzer, G., meta: an R package for meta-analysis. R News 7 (2007), 40–45.
30. 30 Wells, G.A., Sultan, S.A., Chen, L., et al. Indirect treatment comparison [computer program]. Version 1.0. 2009, Canadian Agency for Drugs and Technologies in Health, Ottawa.
31. 31 Rutgeerts, P., Feagan, B.G., Marano, C.W., et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther 42 (2015), 504–514.
32. 32 Sands, B.E., Feagan, B.G., Rutgeerts, P., et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147 (2014), 618–627.e3.
33. 33 Panaccione, R., Ghosh, S., Middleton, S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146 (2014), 392–400.e3.
34. 34 Suzuki, Y., Motoya, S., Hanai, H., et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 49 (2014), 283–294.
35. 35 Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109.e1.
36. 36 Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95.
37. 37 Sandborn, W.J., Feagan, B.G., Rutgeerts, P., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369 (2013), 711–721.
38. 38 Feagan, B.G., Rutgeerts, P., Sands, B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
39. 39 Parikh, A., Leach, T., Wyant, T., et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 18 (2012), 1470–1479.
40. 40 Rutgeerts, P., Van Assche, G., Sandborn, W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 142 (2012), 1102–1111.e2.
41. 41 Watanabe, M., Hibi, T., Lomax, K.G., et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis 6 (2012), 160–173.
42. 42 Sandborn, W.J., van Assche, G., Reinisch, W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142 (2012), 257–265 e1-3.
43. 43 Regueiro, M., El-Hachem, S., Kip, K.E., et al. Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease. Dig Dis Sci 56 (2011), 3610–3615.
44. 44 Sandborn, W.J., Schreiber, S., Feagan, B.G., et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 9 (2011), 670–678.e3.
45. 45 Reinisch, W., Sandborn, W.J., Hommes, D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60 (2011), 780–787.
46. 46 Colombel, J., Sandborn, W., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
47. 47 Feagan, B.G., Greenberg, G.R., Wild, G., et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 6 (2008), 1370–1377.
48. 48 Sandborn, W.J., Hanauer, S.B., Rutgeerts, P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56 (2007), 1232–1239.
49. 49 Schreiber, S., Khaliq-Kareemi, M., Lawrance, I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007), 239–250.
50. 50 Sandborn, W.J., Feagan, B.G., Stoinov, S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007), 228–238.
51. 51 Sandborn, W.J., Rutgeerts, P., Enns, R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007), 829–838.
52. 52 Targan, S.R., Feagan, B.G., Fedorak, R.N., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132 (2007), 1672–1683.
53. 53 Colombel, J.F., Sandborn, W.J., Rutgeerts, P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007), 52–65.
54. 54 Sands, B.E., Kozarek, R., Spainhour, J., et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 13 (2007), 2–11.
55. 55 Lémann, M., Mary, J.Y., Duclos, B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130 (2006), 1054–1061.
56. 56 Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006), 323–333.
57. 57 Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
58. 58 Sandborn, W.J., Colombel, J.F., Enns, R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005), 1912–1925.
59. 59 Schreiber, S., Rutgeerts, P., Fedorak, R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005), 807–818.
60. 60 Feagan, B.G., Greenberg, G.R., Wild, G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352 (2005), 2499–2507.
61. 61 Järnerot, G., Hertervig, E., Friis-Liby, I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005), 1805–1811.
62. 62 Winter, T.A., Wright, J., Ghosh, S., et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 20 (2004), 1337–1346.
63. 63 Sands, B.E., Anderson, F.H., Bernstein, C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004), 876–885.
64. 64 Probert, C.S., Hearing, S.D., Schreiber, S., et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52 (2003), 998–1002.
65. 65 Ghosh, S., Goldin, E., Gordon, F.H., et al. Natalizumab for active Crohn's disease. N Engl J Med 348 (2003), 24–32.
66. 66 Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002), 1541–1549.
67. 67 Sands, B.E., Tremaine, W.J., Sandborn, W.J., et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7 (2001), 83–88.
68. 68 Rutgeerts, P., D'Haens, G., Targan, S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999), 761–769.
69. 69 Present, D.H., Rutgeerts, P., Targan, S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999), 1398–1405.
70. 70 D'Haens, G., Van Deventer, S., Van Hogezand, R., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116 (1999), 1029–1034.
71. 71 Targan, S.R., Hanauer, S.B., van Deventer, S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997), 1029–1035.
72. 72 A phase II multi-center double-blind placebo-controlled parallel-group dose-response study to assess the safety and efficacy of CDP870/certolizumab pegol dosed subcutaneously in patients with active Crohn's disease. Available at: https://clinicaltrials.gov/show/NCT00291668. Accessed June 30, 2016.
73. 73 A phase IIIb multicenter double-blind placebo-controlled randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease (COSPAR I). Available at: https://clinicaltrials.gov/show/NCT00349752. Accessed June 30, 2016.
74. 74 Regueiro M, Feagan BG, Zou B, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease following ileocolonic resection. Gastroenterology (in press).
75. 75 Lichtenstein, G.R., Feagan, B.G., Cohen, R.D., et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 107 (2012), 1409–1422.
76. 76 Schneeweiss, S., Korzenik, J., Solomon, D.H., et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Gastroenterology 150 (2016), 1568–1578.
77. 77 Van Assche, G., Van Ranst, M., Sciot, R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005), 362–368.
78. 78 Ford, A.C., Peyrin-Biroulet, L., Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 108 (2013), 1268–1276.
79. 79 Axelrad, J., Bernheim, O., Colombel, J.F., et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol 14 (2016), 58–64.
80. 80 Nyboe Andersen, N., Pasternak, B., Basit, S., et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 311 (2014), 2406–2413.